
Cagrilintide is an investigational, long-acting amylin analogue that regulates appetite and slows gastric emptying. It is not FDA-approved for standalone weight loss but is currently being evaluated in synergistic combination therapies with GLP-1 agonists like semaglutide to enhance satiety and glycemic control
×